Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 161 clinical trials
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+ HER2- Advanced Breast Cancer

QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing …

aromatase inhibitor
advanced breast cancer
her2/neu-negative breast cancer
letrozole
anastrozole
  • 201 views
  • 27 Jan, 2021
  • 104 locations
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

-placebo in combination with trastuzumab and pertuzumab as maintenance treatment of patients with HER2-positive advanced breast cancer whose tumor harbors a PIK3CA mutation following induction therapy with

  • 0 views
  • 27 Jan, 2021
  • 9 locations
Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Primary Objectives: Dose Escalation: Part A (SAR439859 monotherapy); Part C (combination of SAR439859 with palbociclib); Part F (Safety-Run-In - combination of SAR439859 with alpelisib): -To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR439859 based on the dose-limiting toxicity observance in monotherapy (Part A) and in combination …

aromatase inhibitor
advanced breast cancer
estrogen receptor
measurable disease
palbociclib
  • 904 views
  • 17 Feb, 2021
  • 42 locations
  • 0 views
  • 02 Mar, 2021
  • 96 locations
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have

gonadotropin releasing hormone
cancer treatment
fulvestrant
advanced breast cancer
PIK3CA
  • 506 views
  • 05 Mar, 2021
  • 121 locations
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and

stage iv breast cancer
carcinoma
lumpectomy
locally advanced breast cancer
advanced breast cancer
  • 41 views
  • 27 Jan, 2021
  • 35 locations
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

epidermal growth factor
growth factors
exemestane
EGFR
anastrozole
  • 58 views
  • 03 Mar, 2021
  • 88 locations
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

participants with metastatic or locally advanced breast cancer Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective response

exemestane
anastrozole
estrogen
hormone therapy
fulvestrant
  • 213 views
  • 28 Feb, 2021
  • 164 locations
Management of Low-risk (Grade I and II) DCIS

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, …

breast cancer
estrogen receptor
estrogen
mammogram
erbb2
  • 410 views
  • 17 Feb, 2021
  • 45 locations